Status message

Active context: kki_bg_colors_yellow

Factors Determining Failure to Respond to Treatment in Osteogenesis Imperfecta

Principal Investigator:

Treatment with bisphosphonates is generally effective in increasing bone density and decreasing fracture rate in children with osteogenesis imperfecta. However, adults with osteogenesis imperfecta do not respond to these agents. Also while bisphosphonates administered intravenously are effective in children, oral bisphosphonates are not effective. In our experience, 10-20 % of children may not decrease fracture rate when treated with IV bisphosophonate.

This study will examine multiple factors associated with continued fracture risk in children treated with bisphosphonates. This is a retrospective chart review in children treated with bisphosphonate for more than 2 years who continue to expereince 2 or more fractures per year. A subset of the sample may be contacted by telephone to confirm eligibility and fracture history when chart information is unclear.

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.